Nicholas George Klicos

Array ( [id] => 20386612 [patent_doc_number] => 12486329 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-12-02 [patent_title] => Anti-SIRPa antibody [patent_app_type] => utility [patent_app_number] => 18/660591 [patent_app_country] => US [patent_app_date] => 2024-05-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 41 [patent_figures_cnt] => 41 [patent_no_of_words] => 27578 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 111 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18660591 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19528252 [patent_doc_number] => 20240352154 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-24 [patent_title] => METHODS AND COMPOSITIONS RELATING TO HIGH-THROUGHPUT MODELS FOR ANTIBODY DISCOVERY AND/OR OPTIMIZATION [patent_app_type] => utility [patent_app_number] => 18/607961 [patent_app_country] => US [patent_app_date] => 2024-03-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 48001 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 122 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18607961 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19744047 [patent_doc_number] => 20250032612 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-30 [patent_title] => ANTI-CD276 AND ANTI-CD99 LOGIC GATED CHIMERIC ANTIGEN RECEPTORS FOR THE TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 18/601442 [patent_app_country] => US [patent_app_date] => 2024-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28990 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18601442 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19763209 [patent_doc_number] => 12221483 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2025-02-11 [patent_title] => Fusion protein and nucleic acid encoding sequence thereof, and uses of the same [patent_app_type] => utility [patent_app_number] => 18/426912 [patent_app_country] => US [patent_app_date] => 2024-01-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 19 [patent_no_of_words] => 5301 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18426912 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19248740 [patent_doc_number] => 20240199727 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-20 [patent_title] => ANTI-NGF ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/420296 [patent_app_country] => US [patent_app_date] => 2024-01-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22310 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 519 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18420296 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19248740 [patent_doc_number] => 20240199727 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-20 [patent_title] => ANTI-NGF ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/420296 [patent_app_country] => US [patent_app_date] => 2024-01-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22310 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 519 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18420296 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19248740 [patent_doc_number] => 20240199727 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-20 [patent_title] => ANTI-NGF ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/420296 [patent_app_country] => US [patent_app_date] => 2024-01-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22310 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 519 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18420296 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19491626 [patent_doc_number] => 12110322 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-10-08 [patent_title] => Anti-NGF antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 18/348173 [patent_app_country] => US [patent_app_date] => 2023-07-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 55 [patent_figures_cnt] => 28 [patent_no_of_words] => 22528 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 261 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18348173 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19097793 [patent_doc_number] => 20240117021 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-11 [patent_title] => ANTI-COMPLEMENT C1S ANTIBODY FORMULATION [patent_app_type] => utility [patent_app_number] => 18/334567 [patent_app_country] => US [patent_app_date] => 2023-06-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26297 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18334567 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19202848 [patent_doc_number] => 20240174747 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-30 [patent_title] => T CELL REGULATION [patent_app_type] => utility [patent_app_number] => 18/206552 [patent_app_country] => US [patent_app_date] => 2023-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17790 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18206552 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18784770 [patent_doc_number] => 20230372400 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-23 [patent_title] => METHODS AND COMPOSITIONS INVOLVING INTERLEUKIN-6 RECEPTOR ALPHA-BINDING SINGLE CHAIN VARIABLE FRAGMENTS [patent_app_type] => utility [patent_app_number] => 18/322281 [patent_app_country] => US [patent_app_date] => 2023-05-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22929 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -45 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18322281 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18861960 [patent_doc_number] => 20230416396 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-28 [patent_title] => MULTISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND CD38 AND 4-1BB, AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/319245 [patent_app_country] => US [patent_app_date] => 2023-05-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33683 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -55 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18319245 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18512562 [patent_doc_number] => 20230228768 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-20 [patent_title] => METHODS FOR TREATING AND DIAGNOSING SYSTEMIC LUPUS ERYTHEMATOSUS [patent_app_type] => utility [patent_app_number] => 18/125400 [patent_app_country] => US [patent_app_date] => 2023-03-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11803 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 95 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18125400 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18649450 [patent_doc_number] => 20230295262 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-21 [patent_title] => PROGRAMMED CELLS FOR TARGETED ARTICULAR CARTILAGE AND BONE REGENERATION [patent_app_type] => utility [patent_app_number] => 18/120191 [patent_app_country] => US [patent_app_date] => 2023-03-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10337 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18120191 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18610868 [patent_doc_number] => 20230277598 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-07 [patent_title] => TREATMENT OF TRAUMA ASSOCIATED COGNITIVE DYSFUNCTION USING MESENCHYMAL STEM CELL APOPTOTIC BODIES AND COMPOSITIONS THEREOF [patent_app_type] => utility [patent_app_number] => 18/179212 [patent_app_country] => US [patent_app_date] => 2023-03-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6991 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18179212 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18436055 [patent_doc_number] => 20230183349 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-15 [patent_title] => ANTI-PD1 ANTIBODIES AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 18/178278 [patent_app_country] => US [patent_app_date] => 2023-03-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30780 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18178278 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18649510 [patent_doc_number] => 20230295326 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-21 [patent_title] => ANTAGONISTIC ANTI-TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY POLYPEPTIDES [patent_app_type] => utility [patent_app_number] => 18/152078 [patent_app_country] => US [patent_app_date] => 2023-01-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 86569 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18152078 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18451556 [patent_doc_number] => 20230192834 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-22 [patent_title] => ANTI- TGFB1,2,3 ANTIBODIES AND THERAPEUTIC USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/935590 [patent_app_country] => US [patent_app_date] => 2022-09-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22258 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 58 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17935590 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18241834 [patent_doc_number] => 20230074145 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-09 [patent_title] => Nanobody Target GCC and Uses in Chimeric Antigen Receptor Cell Therapy [patent_app_type] => utility [patent_app_number] => 17/821706 [patent_app_country] => US [patent_app_date] => 2022-08-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28533 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17821706 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18581574 [patent_doc_number] => 20230263826 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-24 [patent_title] => Compositions and Methods for Treatment and Prevention of Type 1 Diabetes [patent_app_type] => utility [patent_app_number] => 17/891020 [patent_app_country] => US [patent_app_date] => 2022-08-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14893 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17891020 [rel_patent_id] =>[rel_patent_doc_number] =>)